Becker's Healthcare September 28, 2022
In collaboration with Helix

Genomic testing has been used for years on a case-by-case basis in clinical care, but is now increasingly seen as an important contributor to advancing population health.

During a September Becker’s Hospital Review webinar sponsored by Helix — a population genomics and viral surveillance company — Feby Abraham, PhD, chief strategy officer of Houston-based Memorial Hermann Health System, and James Lu, MD, PhD, co-founder and CEO of Helix, discussed the role of genomics programs in supporting health systems’ population and precision health objectives.

Three key takeaways were:

  1. Population genomics is an emerging macrotrend that will permeate all parts of healthcare. This outlook is driven by a growing understanding among clinicians of how health determinants — including behavioral, environmental and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Healthcare System, Pharma / Biotech, Population Health Mgmt, Precision Medicine, Provider
How Donald Trump’s return affects hospitals: Medicaid, the Affordable Care Act and tariffs
Investing in adolescent mental health delivers long-term economic and social benefits
The Future of Revenue Cycle Management (RCM) in Healthcare: 4 Key Trends to Watch in 2025
Should Nurse Practitioners Read X-Rays?
NHS trusts warned that ‘legacy debt’ could pose patient safety risk

Share This Article